112 related articles for article (PubMed ID: 19616746)
1. Microscopic gold particle-based fiducial markers for proton therapy of prostate cancer.
Lim YK; Kwak J; Kim DW; Shin D; Yoon M; Park S; Kim JS; Ahn SH; Shin J; Lee SB; Park SY; Pyo HR; Kim DY; Cho KH
Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1609-16. PubMed ID: 19616746
[TBL] [Abstract][Full Text] [Related]
2. Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer.
Cheung J; Kudchadker RJ; Zhu XR; Lee AK; Newhauser WD
Phys Med Biol; 2010 Dec; 55(23):7135-47. PubMed ID: 21076190
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel liquid fiducial marker for multimodal image guidance in stereotactic body radiotherapy of prostate cancer.
De Roover R; Crijns W; Poels K; Peeters R; Draulans C; Haustermans K; Depuydt T
Med Phys; 2018 May; 45(5):2205-2217. PubMed ID: 29537613
[TBL] [Abstract][Full Text] [Related]
4. Preclinical investigation for developing injectable fiducial markers using a mixture of BaSO4 and biodegradable polymer for proton therapy.
Ahn SH; Gil MS; Lee DS; Han Y; Park HC; Sohn JW; Kim HY; Shin EH; Yu JI; Noh JM; Cho JS; Ahn SH; Choi DH
Med Phys; 2015 May; 42(5):2626-37. PubMed ID: 25979054
[TBL] [Abstract][Full Text] [Related]
5. Investigation of dose perturbations and the radiographic visibility of potential fiducials for proton radiation therapy of the prostate.
Huang JY; Newhauser WD; Zhu XR; Lee AK; Kudchadker RJ
Phys Med Biol; 2011 Aug; 56(16):5287-302. PubMed ID: 21799236
[TBL] [Abstract][Full Text] [Related]
6. Fiducial markers implanted during prostate brachytherapy for guiding conformal external beam radiation therapy.
Welsh JS; Berta C; Borzillary S; Sam C; Shickell D; Nobile L; Greenberg M; Weiss S; Detorie N
Technol Cancer Res Treat; 2004 Aug; 3(4):359-64. PubMed ID: 15270586
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of using fewer implanted fiducial markers for prostate target alignment.
Kudchadker RJ; Lee AK; Yu ZH; Johnson JL; Zhang L; Zhang Y; Amos RA; Nakanishi H; Ochiai A; Dong L
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1283-9. PubMed ID: 19427750
[TBL] [Abstract][Full Text] [Related]
8. Fiducial markers in prostate for kV imaging: quantification of visibility and optimization of imaging conditions.
Chen Y; O'Connell JJ; Ko CJ; Mayer RR; Belard A; McDonough JE
Phys Med Biol; 2012 Jan; 57(1):155-72. PubMed ID: 22127351
[TBL] [Abstract][Full Text] [Related]
9. Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate.
Newhauser W; Fontenot J; Koch N; Dong L; Lee A; Zheng Y; Waters L; Mohan R
Phys Med Biol; 2007 Jun; 52(11):2937-52. PubMed ID: 17505081
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy.
Habermehl D; Henkner K; Ecker S; Jäkel O; Debus J; Combs SE
J Radiat Res; 2013 Jul; 54 Suppl 1(Suppl 1):i61-8. PubMed ID: 23824129
[TBL] [Abstract][Full Text] [Related]
11. Visibility and artifacts of gold fiducial markers used for image guided radiation therapy of pancreatic cancer on MRI.
Gurney-Champion OJ; Lens E; van der Horst A; Houweling AC; Klaassen R; van Hooft JE; Stoker J; van Tienhoven G; Nederveen AJ; Bel A
Med Phys; 2015 May; 42(5):2638-47. PubMed ID: 25979055
[TBL] [Abstract][Full Text] [Related]
12. Determination of optimal fiducial marker across image-guided radiation therapy (IGRT) modalities: visibility and artifact analysis of gold, carbon, and polymer fiducial markers.
Handsfield LL; Yue NJ; Zhou J; Chen T; Goyal S
J Appl Clin Med Phys; 2012 Sep; 13(5):3976. PubMed ID: 22955665
[TBL] [Abstract][Full Text] [Related]
13. Quantification of MRI visibility and artifacts at 3T of liquid fiducial marker in a pancreas tissue-mimicking phantom.
Schneider S; Jølck RI; Troost EGC; Hoffmann AL
Med Phys; 2018 Jan; 45(1):37-47. PubMed ID: 29136287
[TBL] [Abstract][Full Text] [Related]
14. Biological effect of dose distortion by fiducial markers in spot-scanning proton therapy with a limited number of fields: a simulation study.
Matsuura T; Maeda K; Sutherland K; Takayanagi T; Shimizu S; Takao S; Miyamoto N; Nihongi H; Toramatsu C; Nagamine Y; Fujimoto R; Suzuki R; Ishikawa M; Umegaki K; Shirato H
Med Phys; 2012 Sep; 39(9):5584-91. PubMed ID: 22957624
[TBL] [Abstract][Full Text] [Related]
15. Quantification and comparison of visibility and image artifacts of a new liquid fiducial marker in a lung phantom for image-guided radiation therapy.
Scherman Rydhög J; Irming Jølck R; Andresen TL; Munck Af Rosenschöld P
Med Phys; 2015 Jun; 42(6):2818-26. PubMed ID: 26127034
[TBL] [Abstract][Full Text] [Related]
16. Novel artifact-robust and highly visible zinc solid fiducial marker for kilovoltage x-ray image-guided radiation therapy.
Wang T; Inubushi S; Ikeo N; Mukai T; Okumura K; Akasaka H; Yada R; Yoshida K; Miyawaki D; Ishihara T; Nakaoka A; Sasaki R
Med Phys; 2020 Oct; 47(10):4703-4710. PubMed ID: 32696571
[TBL] [Abstract][Full Text] [Related]
17. Dose perturbations from implanted helical gold markers in proton therapy of prostate cancer.
Giebeler A; Fontenot J; Balter P; Ciangaru G; Zhu R; Newhauser W
J Appl Clin Med Phys; 2009 Jan; 10(1):2875. PubMed ID: 19223836
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image Guided Stereotactic Body Radiation Therapy in the Abdomen.
Slagowski JM; Colbert LE; Cazacu IM; Singh BS; Martin R; Koay EJ; Taniguchi CM; Koong AC; Bhutani MS; Herman JM; Beddar S
Pract Radiat Oncol; 2020; 10(6):434-442. PubMed ID: 31988039
[TBL] [Abstract][Full Text] [Related]
19. Improving positioning in high-dose radiotherapy for prostate cancer: safety and visibility of frequently used gold fiducial markers.
Fonteyne V; Ost P; Villeirs G; Oosterlinck W; Impens A; De Gersem W; De Wagter C; De Meerleer G
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):46-52. PubMed ID: 22014956
[TBL] [Abstract][Full Text] [Related]
20. Novel image-guided marker aimed at organ-preserving therapies for prostate cancer.
Okihara K; Ueda T; Fujihara A; Shiraishi T; Iwasaki H; Nomoto T; Masui K; Ito-Ihara T; Hara E; Nakai R; Shiina T; Ukimura O
Int J Urol; 2024 May; 31(5):500-506. PubMed ID: 38193342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
